Caroline Ingre's research group - our research
ALS (amyotrophic lateral sclerosis) is a fatal neuromuscular disease that is characterized by a degeneration of upper and lower motorneurons. The patients experience a weakness usually starting in the upper or lower extremities spreading to other regions weakening both speech and swallowing. Besides the muscle weakness, cognitive dysfunction and behavioral changes are seen in about 50% of the patients and some develop fulminant frontotemporal dementia.
There is no single test that provides the ALS diagnosis. The diagnosis is based on clinical and electrophysiological signs, and the exclusion of other diseases. Little information can thus be given to the patient about the course of the disease. The disease has no cure. The aim with our research is to increase the knowledge about several aspects of the disease, and ultimately find a cure.
My group works within many areas of the ALS disease. We have created a national quality registry, a tissue biobank, an imaging bank and collected data on lifestyle and environment. We also conduct clinical trials on ALS.
- Risc and correlations to exposure
- Spreading patterns and phenotypic expression
- Prognosis and survival
- Quality of life and depression
- Cognitive status
- Tissue biomarkers
- Imaging biomarkers
- Genetic expression
- Clinical trials
Read more about the ALS Clinical Research Group
ALS Clinical Research Group
The group strives to integrate ALS research and care by conducting clinical research. The main interests of the group are risk and prognosis of ALS disease, the development of imaging methods, biomarker studies and psychological and cognitive influence on ALS. The group is also conductiong several clinical trials in ALS.